Harrow Health Inc (NASDAQ:HROW) — Market Cap & Net Worth
Market Cap & Net Worth: Harrow Health Inc (HROW)
Harrow Health Inc (NASDAQ:HROW) has a market capitalization of $1.24 Billion ($1.24 Billion) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #7991 globally and #2360 in its home market, demonstrating a -11.77% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Harrow Health Inc's stock price $33.13 by its total outstanding shares 37487850 (37.49 Million). Also see Harrow Health Inc (HROW) total assets for a full breakdown of the balance sheet.
Harrow Health Inc Market Cap History: 2015 to 2026
Harrow Health Inc's market capitalization history from 2015 to 2026. Data shows growth from $259.79 Million to $1.24 Billion (15.68% CAGR). Also see HROW cash flow metrics for how efficiently the company converts equity into cash flow.
Index Memberships
Harrow Health Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.05% | #234 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #875 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.07% | #138 of 263 |
Weight: Harrow Health Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Harrow Health Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Harrow Health Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Harrow Health Inc (HROW) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
6.75x
Harrow Health Inc's market cap is 6.75 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $93.72 Million | $19.94 Million | -$19.09 Million | 4.70x | N/A |
| 2017 | $63.73 Million | $26.77 Million | -$11.98 Million | 2.38x | N/A |
| 2018 | $213.31 Million | $41.37 Million | $14.62 Million | 5.16x | 14.59x |
| 2019 | $291.66 Million | $51.16 Million | $168.00K | 5.70x | 1736.04x |
| 2020 | $257.17 Million | $48.87 Million | -$3.36 Million | 5.26x | N/A |
| 2021 | $323.90 Million | $72.48 Million | -$18.01 Million | 4.47x | N/A |
| 2022 | $553.32 Million | $88.59 Million | -$14.09 Million | 6.25x | N/A |
| 2023 | $419.86 Million | $130.19 Million | -$24.41 Million | 3.22x | N/A |
| 2024 | $1.26 Billion | $199.61 Million | -$17.48 Million | 6.30x | N/A |
| 2025 | $1.84 Billion | $272.30 Million | -$5.14 Million | 6.75x | N/A |
Competitor Companies of HROW by Market Capitalization
Companies near Harrow Health Inc in the global market cap rankings as of September 18, 2026. Review HROW goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Harrow Health Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #520 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #619 globally with a market cap of $44.48 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #637 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Haleon plc (NYSE:HLN): Ranked #665 globally with a market cap of $41.22 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #520 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #619 | GALDERMA GROUP AG | NYSE:GALDY | $44.48 Billion | $38.15 |
| #637 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.10 |
| #665 | Haleon plc | NYSE:HLN | $41.22 Billion | $9.36 |
Harrow Health Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Harrow Health Inc's market cap moved from $259.79 Million to $ 1.24 Billion, with a yearly change of 15.68%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.24 Billion | -32.39% |
| 2025 | $1.84 Billion | +46.05% |
| 2024 | $1.26 Billion | +199.55% |
| 2023 | $419.86 Million | -24.12% |
| 2022 | $553.32 Million | +70.83% |
| 2021 | $323.90 Million | +25.95% |
| 2020 | $257.17 Million | -11.83% |
| 2019 | $291.66 Million | +36.73% |
| 2018 | $213.31 Million | +234.71% |
| 2017 | $63.73 Million | -32.00% |
| 2016 | $93.72 Million | -63.92% |
| 2015 | $259.79 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Harrow Health Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.24 Billion USD |
| MoneyControl | $1.24 Billion USD |
| MarketWatch | $1.24 Billion USD |
| marketcap.company | $1.24 Billion USD |
| Reuters | $1.24 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Harrow Health Inc
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, in… Read more